Hello, my name is Dr. Kevin Pollock from Health Protection Scotland,
and I'm going to deliver a presentation on
the impact of Human Papilloma Virus (HPV) vaccine program within the United Kingdom.
The format of this presentation will take the listener through the following:
What is the Human Papilloma Virus?
How do we implement and monitor HPV infection through surveillance?
It's absolutely important to realize that vaccine uptake and
high maintenance of that vaccine uptake is integral to the success of the program.
As with any other new vaccine program which has been implemented,
it is incredibly important to monitor adverse events as and when they arise.
It is also very important and critical to the success of
the vaccine program that we monitor the effectiveness of the vaccine.
We can do that individually, and at the population level.
I will also discuss future work in setting the
the program and how this may impact on cervical screening.
I will round off with some conclusions to the piece of work so far.
There're approximately 3,000 cases of
cervical cancer throughout the United Kingdom every year.
Approximately one third of these women will die.
Not withstanding the significant number of cervical abnormalities which are diagnosed
every year - leading to psychological burden and mental anguish for these ladies.
If we consider cervical cancer in other parts of the world, it's a very,
very serious public health problem; with
approximately one death every two minutes each year worldwide.
Given that there are fewer screening programs and very low uptake of vaccine, if at all -
the mortality rates associated with
cervical cancer are very high in the developing world.
The main risk factors for
cervical cancer are infection with Human Papilloma Virus or HPV,
tobacco smoking and socio-economic status.